20
As Big Pharma’s development pipeline shows growing amounts of next-generation engineered antibody formats, further complexity has been added to the process development and biomanufacturing of biologics. Today, we have more than 100 different formats for biospecific antibodies alone, says Thomas Schirrmann, CEO of antibody discovery and development specialist Yumab GmbH (Braunschweig, Germany). Yumab cofounder Stefan Dübel confirms that classical mAbs today make up only a third of all drug candidates in the development pipeline of companies like Roche. The newly-engineered antibody formats, together with the current hype around cell and gene…